Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia

Yaneth Gil-Rojas¹, Pieralessandro Lasalvia¹

¹Neuroeconomix, Bogotá, CUN, Colombia. This study received funding from Boehringer Ingelheim Colombia

Objective

 Thrombolysis is effective for treating acute ischemic stroke. Trials have evaluated its effectiveness at 90, 180 and 270 minutes after stroke. The objective of the study was to evaluate the clinical and budgetary impact of increasing the proportion of thrombolyzed acute ischemic stroke patients in Colombia

Methods

Figure 1. Model structure



Table 1. Market share of the technologies

Current scenario					
	Year 1	Year 2	Year 3	Year 4	Year 5
Thrombolyzed patients (%)	8%	9%	10%	11%	12%
Alteplase	2,618	3,001	3,398	3,809	4,234
Conservative management					
only	30,109	30,347	30,584	30,819	31,052
New scenario					
	Year 1	Year 2	Year 3	Year 4	Year 5
Thrombolyzed patients (%)	16%	18%	20%	22%	24%
Alteplase	5,236	6,003	6,796	7,618	8,469
Conservative management					
only	27,491	27,346	27,186	27,010	26,817

References

- Rajsic S, Gothe H, Borba HH, et al. Economic burden of stroke: a systematic review on post-stroke care. Eur J Heal Econ. 2019;20:107–134.
 Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Compare Data Visualization [Internet]. Seattle, WA IHME, Univ. Washingt. 2019. Available from: https://vizhub.healthdata.org/gbd-compare/
 - Saposnik G, Del Brutto OH. Stroke in South America: A systematic review of incidence, prevalence, and stroke subtypes. Stroke. 2003;34:2103–2107.
- 4. Sudlow CLM, Warlow CP. Comparable Studies of the Incidence of Stroke and its Pathological Types. Stroke. 1997;28:491–499.
 - Departamento Administrativo Nacional de Estadísticas (DANE). Proyecciones y retroproyecciones de población nacional para el periodo 1950-2017 y 2018-2070 con base en el CNPV 2018 [Internet]. 2020 [cited 2020 Oct 21]. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion.
- 6. Instituto Nacional de Vigilancia de Medicamentos y Alimentos INVIMA. Consulta de registros sanitarios [Internet]. 2020. Available from: http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp.
 7. Ministerio de Salud y Protección Social (MSPS). Cubo de Suficiencia UPC. Consulta para el periodo 2016-2019. [Internet]. 10-06-2021; 2021. Available from: https://www.sispro.gov.co/Pages/Home.aspx.
 - Dawson J, Lees JS, Chang T-P, et al. Association Between Disability Measures and Healthcare Costs After Initial Treatment for Acute Stroke. Stroke. 2007;38:1893–1898.

Table 2. Costs related to thrombolysis

Cost category	Minimum	Maximum	Average	Source	
Treatment costs					
Conservative treatment	415.31	561.69	438.32	[22]	
Alteplase - rtPA	607.29	853.23	647.00	[22]	
Administration costs					
Intravenous thrombolysis	98.49	116.61	102.43	ISS+30%	
Follow-up costs					
Additional follow-up	217.65	257.70	226.36	[22]	

- •We developed a budget impact modal estimating with a 5-year time horizon from the perspective of the third-party payer in Colombia.
- •We obtained epidemiological data from local sources and published studies. We established healthcare resource utilization with base case with local clinical experts and costing was performed with local tariff manuels.
- •Efficacy data was extracted from published literature.
- •We considered three windows for treatment initiation: 0-90, 91-180, and 181-270 minutes. Costs were expressed in US dollars of 2020. (2020, 1 USD = \$3,693.36 COP)

Results

Table 3. budgetary analysis of ischemic stroke in a 5-year time horizon

,	0-90 minutes	91-180 minutes	181-270 minutes		
Current scenario	\$ 282,399,907	\$ 293,441,882	\$ 242,995,643		
New scenario	\$ 297,925,556	\$ 310,107,186	\$ 259,958,874		
Annual BI	\$ 15,525,649	\$ 16,665,304	\$ 16,963,231		
Relative annual BI	5.5%	5.7%	7.0%		
BIA details					
Acquisition	\$ 11,038,558	\$ 11,038,558	\$ 11,038,558		
Administration	\$ 1,747,528	\$ 1,747,528	\$ 1,747,528		
Follow-up	\$ 3,861,977	\$ 3,861,977	\$ 3,861,977		
Favorable outcome	\$ 236,146	\$ 845,158	\$ 264,417		
Unfavorable outcome	-\$ 2,689,831	-\$ 2,599,914	-\$ 865,202		
Adverse events	\$ 1,831,582	\$ 2,529,748	\$ 1,179,959		
Rehabilitation	-\$ 500,311	-\$ 757,752	-\$ 264,006		
Difference of events					
Without sequelae (Rankin 0-1)	1,872	2,151	1,245		
With sequelae (Rankin 2-5)	-1,721	-2,594	-1,007		
Deaths (Rankin 6)	-151	443	-239		

Results

Table 4. 5-year cumulative budgetary impact and sensitivity analysis

	Budget impact	Relative	Events avoided
Analysis	(USD\$)	change	(Sequelae and deaths)
Analysis 0-90 min (10% vs 22%)	\$ 15,525,649	5.5%	-1,872
Price of intervention - minimum	\$ 14,848,134	5.3%	-1,872
Price of intervention - maximum	\$ 19,044,230	6.7%	-1,872
Cost of events - Minimum	\$ 15,376,894	5.7%	-1,872
Cost of events - Maximum	\$ 15,555,260	4.4%	-1,872
New scenario (10% vs 45%)	\$ 47,087,685	16.7%	-5,659
Analysis 91-180 min (10% vs 22%)	\$ 16,665,304	5.7%	-2,151
Price of intervention - minimum	\$ 15,987,789	5.5%	-2,151
Price of intervention - maximum	\$ 20,183,885	6.8%	-2,151
Cost of events - Minimum	\$ 16,476,677	5.9%	-2,151
Cost of events - Maximum	\$ 16,792,655	4.5%	-2,151
New scenario (10% vs 45%)	\$ 50,615,362	17.2%	-6,502
Analysis 181-270 min (10% vs 22%)	\$ 16,963,231	7.0%	-1,245
Price of intervention - minimum	\$ 16,285,717	6.7%	-1,245
Price of intervention - maximum	\$ 20,481,813	8.3%	-1,245
Cost of events - Minimum	\$ 16,729,331	7.2%	-1,245
Cost of events - Maximum	\$ 17,795,993	5.8%	-1,245
New scenario (10% vs 45%)	\$ 51,356,524	21.1%	-3,764
Changes at the start of treatment			
NINDS (0-180 min)	\$ 17,110,335	5.6%	-2,218
Lee et al (181-270 min)	\$ 17,200,906	6.4%	-1,174

Conclusion

From the perspective evaluated, doubling the number of patients with AIS who are thrombolyzed would lead to reductions in the number of patients with sequelae and would require a budgetary effort of 5.5-7.0%. The early initiation of treatment (0-180minutes) gives an additional benefit in reducing the number of sequelae and a lower budgetary impact than initiation within the last time window (181-270minutes).

